Sustained CLL Clearance With Ven-Obi Supports Durable Immune Recovery Fixed-duration venetoclax–obinutuzumab sustained chronic lymphocytic leukemia (CLL) cell depletion while permitting measured immune recovery.

Venetoclax–obinutuzumab (#VenObi) demonstrated durable disease control with partial but steady immune restoration through 48 months. @ash.hematology.org

Read more: https://bit.ly/482ZHOf

#RareDisease #ChronicLymphocyticLeukemia #CLL #Hematology